Distinguishing hyperparathyroidism from insulin-like growth factor I–driven calcium–phosphate metabolism changes in acromegaly
Open Access
- 28 August 2026
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (3) , 508-517
Abstract
Objectives: Acromegaly is frequently associated with disturbances in calcium–phosphate metabolism, including mild hypercalcemia. Hypercalcemia may also reflect primary hyperparathyroidism (PHPT), which can occur with or without variants in MEN1 or the related genes. Distinguishing PHPT from insulin-like growth factor I (IGF-I)–related alterations in mineral metabolism remains challenging. We aimed to assess the prevalence and characteristics of PHPT in patients with acromegaly and explore biochemical approaches for identifying parathyroid autonomy. Design: We conducted a retrospective study at 2 French university hospitals, including adults with acromegaly who had at least 1 serum calcium measurement obtained during uncontrolled disease. Three diagnostic approaches based on serum calcium and phosphate levels were evaluated: a threshold-based decision rule, logistic regression, and a support vector machine model. Results: Among 393 patients (54% women; median age 43 years [interquatile range 33-55]), 23 (5.9%) had concomitant PHPT. In isolated acromegaly, hyperphosphatemia occurred in 37.3% and mild hypercalcemia in 3.2% of patients; both resolved after acromegaly treatment. Patients with PHPT had persistent mild hypercalcemia (median calcium 2.72 mmol/L [interquatile range 2.66-2.86]), elevated PTH, and low-to-normal phosphate levels, these abnormalities resolved after parathyroid surgery in the 10 operated patients. No pathogenic variants were identified in the tested genes. A threshold-based rule combining calcium >2.60 mmol/L and phosphate <1.46 mmol/L showed excellent diagnostic performance for identifying parathyroid autonomy, with bootstrap 0.632+ corrected sensitivity and specificity of 0.940 and 0.993, respectively, and was preferred because of its simplicity. Conclusions: PHPT may be more frequent in acromegaly than in the general population. In patients with acromegaly and hypercalcemia, a nonelevated phosphate level strongly suggests concomitant PHPT, whereas an elevated phosphate level favors IGF-I–related mineral disturbances.Keywords
This publication has 22 references indexed in Scilit:
- Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practiceThe Lancet Diabetes & Endocrinology, 2025
- Chapter 5: The roles of genetics in primary hyperparathyroidismAnnales d'Endocrinologie, 2025
- French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1Annales d'Endocrinologie, 2023
- Acromegaly: pathogenesis, diagnosis, and managementThe Lancet Diabetes & Endocrinology, 2022
- Clinical aspects of multiple endocrine neoplasia type 1Nature Reviews Endocrinology, 2021
- True MEN1 or phenocopy? Evidence for geno-phenotypic correlations in MEN1 syndromeEndocrine, 2019
- Germ-line mutations in p27
Kip1
cause a multiple endocrine neoplasia syndrome in rats and humansProceedings of the National Academy of Sciences, 2006
- Hyperparathyroidism in multiple endocrine neoplasia type I: Surgical trends and results of a 256‐patient series from groupe d’Etude des Néoplasies endocriniennes multiples study groupWorld Journal of Surgery, 2001
- Positional Cloning of the Gene for Multiple Endocrine Neoplasia-Type 1Science, 1997
- Effect of growth hormone on vitamin D metabolismNature, 1978